背景:COVID-19的自发性气胸很少发生,但在多达15%的依赖机械通气(MV)的患者中发生。气胸相关死亡占所有COVID-19相关死亡的1%。
目的:确定与COVID-19患者气胸相关的因素以及气胸对早期生存的影响。
方法:这是一项对4799例COVID-19阳性住院患者的回顾性研究。两组均为67名COVID-19患者,采用倾向评分匹配(PSM)对两组进行均质化。确定气胸的患病率。采用多因素logistic回归分析气胸相关因素。P值<0.05为显著的。
结果:COVID-19患者气胸患病率为1.6%。肺部疾病,合并症,和氧气支持,PSM前两组之间存在显着差异,PSM后均质化。在单变量分析中,症状持续时间(P<0.001),中性粒细胞增多症(P<0.001),淋巴细胞减少(P=0.001),中性粒细胞-淋巴细胞比值(P=0.003),铁蛋白水平(P=0.012),D-二聚体水平(P=0.011),MV支持(P=0.001),抗生素治疗(P<0.001),住院时间(P=0.009),和死亡(P=0.002)在组间有显著差异。气胸对生存率有显著的负面影响(32.8%vs.59.7%,P=0.01)。在多元回归模型中,与气胸相关的因素是症状持续时间(校正比值比(AOR)1.68;95%置信区间(CI):1.26-2.25;P=0.001),机械通气(AOR23.92;95%CI:4.12-138.72;P=<0.001),双重抗生素(AOR8.28;95%CI:1.56-43.86;P=0.013),中性粒细胞增多(AOR:1.08;95%CI:1.02-1.14;P=0.011),和淋巴细胞减少(AOR:0.92;95%CI:0.86-0.90;P=0.022)。
结论:在COVID-19患者中,气胸的存在与低生存率相关。从症状发作到治疗的时间较长的患者以及在重症监护中依赖机械通气的患者属于气胸发展的高风险组。
BACKGROUND: Spontaneous pneumothorax in COVID-19 occurs infrequently but in up to 15% of patients dependent on mechanical ventilation (MV).
Pneumothorax-related deaths account for 1% of all COVID-19-related deaths.
OBJECTIVE: To determine factors associated with pneumothorax in COVID-19 patients and the effect of
pneumothorax on early survival.
METHODS: This was a retrospective study of 4799 COVID-19-positive hospitalized patients. The groups were homogenized using propensity score matching (PSM) in two groups comprising 67 COVID-19 patients each. The prevalence of
pneumothorax was determined. Multiple logistic regression was used to determine factors associated with
pneumothorax. P value < 0.05 was taken as significant.
RESULTS: The prevalence of
pneumothorax in COVID-19 patients was 1.6%. Lung disease, comorbidities, and oxygen support, which were significantly different between the two groups before PSM, were homogenized after PSM. In a univariate analysis, symptom duration (P ˂ 0.001), neutrophilia (P ˂ 0.001), lymphopenia (P ˂ 0.001), neutrophil-lymphocyte ratio (P = 0.003), ferritin levels (P = 0.012), D-dimer levels (P = 0.011), MV support (P ˂ 0.001), antibiotherapy (P ˂ 0.001), length of hospital stay (P = 0.009), and death (P = 0.002) differed significantly between the groups. Pneumothorax had a significant negative effect on survival (32.8% vs. 59.7%, P = 0.01). In a multivariate regression model, factors associated with pneumothorax were duration of symptoms (Adjusted Odds ratio (AOR) 1.68; 95% Confidence Interval (CI): 1.26-2.25; P = 0.001), mechanical ventilation (AOR 23.92; 95% CI: 4.12-138.72; P = <0.001), dual antibiotics (AOR 8.28; 95% CI: 1.56-43.86; P = 0.013), neutrophilia (AOR: 1.08; 95% CI: 1.02-1.14; P = 0.011), and lymphopenia (AOR: 0.92; 95% CI: 0.86-0.90; P = 0.022).
CONCLUSIONS: The presence of pneumothorax was associated with poor survival in COVID-19 patients. Patients with a prolonged time from symptom onset to treatment and those dependent on mechanical ventilation in intensive care were in the high risk group for the development of pneumothorax.